Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options.

Autor: Kurita Y; Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama 236-0004, Japan.; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan., Kobayashi N; Department of Oncology, Yokohama City University Hospital, Yokohama 236-0004, Japan., Hara K; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan., Mizuno N; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan., Kuwahara T; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan., Okuno N; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan., Haba S; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan., Tokuhisa M; Department of Oncology, Yokohama City University Hospital, Yokohama 236-0004, Japan., Hasegawa S; Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama 236-0004, Japan., Kubota K; Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama 236-0004, Japan., Nakajima A; Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama 236-0004, Japan., Ichikawa Y; Department of Oncology, Yokohama City University Hospital, Yokohama 236-0004, Japan.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2022 Nov 18; Vol. 14 (22). Date of Electronic Publication: 2022 Nov 18.
DOI: 10.3390/cancers14225669
Abstrakt: Background: The clinical outcomes of everolimus rechallenge in patients with pancreatic neuroendocrine neoplasms (PNENs) are unknown. This study aimed to investigate the treatment outcomes and safety of everolimus rechallenge treatment with PNENs.
Methods: Clinical data of everolimus-treated patients with PNENs at two institutions were collected. Patients who underwent everolimus rechallenge were included in the study. We analyzed the progression-free survival (PFS) and treatment response associated with everolimus rechallenge and the adverse events.
Results: Between 2008 and 2020, 117 patients received initial treatment with everolimus, of which 14 patients received everolimus rechallenge. With regard to the grade of PNENs, there were 2 cases of G1, 11 cases of G2, and 1 case of G3. The median rechallenge PFS was 5.7 months. The objective response rate was 21.4%. the disease control rate was 71.4%. The only major grade 3 or 4 adverse event was neutropenia ( n = 1, 7.1%). No other severe adverse event was observed.
Conclusion: The outcomes and safety of everolimus rechallenge were verified, and it was deemed an acceptable treatment. Everolimus rechallenge may provide a new drug therapy for patients with advanced PNENs for whom no other drug treatment option is available.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje